Last updated: November 28, 2023
Sponsor: Euromi Biosciences
Overall Status: Active - Recruiting
Phase
N/A
Condition
N/ATreatment
Breast reconstruction
Clinical Study ID
NCT05987475
ID RCB: 2023-A00101-44
Ages 18-60 Female Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Female;
- 18 years old and above, and under 60 years old;
- has approved and signed the informed consent form;
- eligible to receive at least one EUROMI Biosciences implant during breastreconstruction following a mastectomy or during aesthetic breast surgery;
- Willing to be followed up for a period of 10 years.
Exclusion
Exclusion Criteria:
- Informed pregnancy or breastfeeding at the time of inclusion
- Known hypersensitivity and / or allergy to silicone;
- Not understanding or not accepting the risks of further surgeries during follow-up;
- Body mass index > 40 kg/m²;
- Diabetes
- HbA1c levels > 7,5%;
- History of repeated failure with the implantation of similar implants;
- Tissue or fat insufficiency;
- Progressive breast cancer large tumours (>5 cm), late cancer stage and deep tumours;
- Grossly positive axillary involvement / or chest wall involvement;
- High risk of cancer recurrence;
- Tissue damage in the implant area due to irradiation of the thoracic wall;
- Pre-existing pathology in the implant area;
- General infection or infection in the implant area;
- Medical condition (poor physiological condition, psychological instability, severesmoking, obesity, coagulopathy, diabetes, severe cardiovascular or pulmonary disease,etc.) Which may, according to the judgement of the surgeon, entail excessive riskand/or post-surgical complications;
- History or presence of an autoimmune disease;
- Immunocompromised;
- History or current treatment using radiation with lower-pole scarring and thin, poorlyvascularized skin/tissue / microwave diathermy / or steroids;
- Medical condition likely to interfere with her capacity to understand the follow-uprequirements, to participate in the follow-up or to give her informed consent;
- Concomitantly part of another interventional clinical trial.
- Under supervision or legal guardianship
- Deprived of liberty by a judicial or administrative decision
- Not affiliated to health insurance system or is a beneficiary of such coverage
Study Design
Total Participants: 177
Treatment Group(s): 1
Primary Treatment: Breast reconstruction
Phase:
Study Start date:
October 18, 2023
Estimated Completion Date:
September 30, 2034
Connect with a study center
CHRU Nancy
Nancy,
FranceActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.